FDA Declares End to Tirzepatide Shortage While compounded GLP-1s served an important role during drug shortages, they are not considered identical to FDA-approved brand-name medications Mounjaro/Zepbound, Eli Lilly GLP-1 injectables are no longer in “short supply”. Thus compounding pharmacies can no longer legally compound it. Starting in 2025, once the Medicare pt pays $2,000 (deductibles […]
Filed under: General Problems | Leave a Comment »